Patents by Inventor Julie Nye

Julie Nye has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adenovirus E1B-55K single amino acid mutants and methods of use
    Patent number: 7785887
    Abstract: Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: August 31, 2010
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Yuqiao Shen, Julie Nye, Terry Hermiston
  • Adenovirus E1B-55K single amino acid mutants and methods of use
    Publication number: 20050053581
    Abstract: Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.
    Type: Application
    Filed: September 24, 2003
    Publication date: March 10, 2005
    Inventors: Yuqiao Shen, Julie Nye, Terry Hermiston
  • Adenovirus E1B shuttle vectors
    Patent number: 6764674
    Abstract: Provided are replication competent, recombinant adenovirus vectors containing mutations in the E1B region which permit the easy deletion of a gene or genes therein, and optionally the substitution therefore of a heterologous gene that substantially exhibits the temporal expression pattern of the E1b region gene(s) deleted. Such vectors have applications for the treatment of disease, and preferably for the treatment of neoplastic disease.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: July 20, 2004
    Assignee: Onyx Pharmaceuticals Inc.
    Inventors: Terry Hermiston, Julie Nye
  • Adenovirus E1B-55K single amino acid mutants and methods of use
    Patent number: 6635244
    Abstract: Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.
    Type: Grant
    Filed: July 30, 2001
    Date of Patent: October 21, 2003
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Yuqiao Shen, Julie Nye, Terry Hermiston
  • Adenovirus E1B-55K single amino acid mutants and methods of use
    Publication number: 20030003076
    Abstract: Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.
    Type: Application
    Filed: July 30, 2001
    Publication date: January 2, 2003
    Inventors: Yuqiao Shen, Julie Nye, Terry Hermiston
  • Cytopathic adenoviral E1B mutated viruses for therapy and prophylaxis of neoplasia
    Patent number: 6080578
    Abstract: Methods and compositions for treating neoplastic conditions by viral-based therapy are provided. Mutant virus lacking viral proteins which bind and/or inactivate p53 or RB are administered to a patient having a neoplasm which comprises cells lacking p53 and/or RB function. The mutant virus is able to substantially produce a replication phenotype in neoplastic cells but is substantially unable to produce a replication phenotype in non-replicating, non-neoplastic cells having essentially normal p53 and/or RB function. The preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.
    Type: Grant
    Filed: December 8, 1997
    Date of Patent: June 27, 2000
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: James R. Bischoff, Julie Nye, Lelia Ng, Sharon Horn, Angelica Williams, David Kirn